VBI Vaccines (VBIV) PT Lowered to $5 at Canaccord Genuity

Canaccord Genuity analyst John Newman lowered the price target on VBI Vaccines (NASDAQ: VBIV) to $5.00 (from $10.00) while maintaining a Buy rating.

Analyst comments: "We maintain our BUY rating and are reducing our price target to $5 from $10 after moderating our launch estimate in the US due to less-clear competitive positioning vs Heplisav-B. We continue to believe Sci-B-Vac will be viewed positively by regulators and achieve approval in the US and EU after positive readout in CONSTANT later this year."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities